drugset / Trial / NCT05290597
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Phase 1
Active not recruiting
40 enrolled
Innovent Biologics (Suzhou) Co. Ltd.
Fortvita Biologics (USA)Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI363 (study drug) in subjects with advanced, refractory solid malignancies or lymphomas.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2026-01-28
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI363 | Protein / enzyme biologic | — | — |